Euvax B (recombinant hepatitis B vaccine) / LG Chem - LARVOL DELTA

A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area. (PubMed, PLoS Negl Trop Dis) - P1 | "Vaccination of adults with Sm-TSP-2/Alhydrogel in an area of ongoing S. mansoni transmission was safe, minimally reactogenic, and elicited significant IgG and IgG subclass responses against the vaccine antigen. These promising results have led to initiation of a Phase 2 clinical trial of this vaccine in an endemic region of Uganda."

Journal • P1 data • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Pain • TLR4 • TSPAN2

COMBAT-HBV: The COMBAT HBV Feasibility Trial (clinicaltrials.gov) - P4 | N=560 | Not yet recruiting | Sponsor: University of North Carolina, Chapel Hill

New P4 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation

The Effects of Offering Freedom to Comply by Pediatricians and Nurses, Using the But-You-Are-Free (BYAF) Technique, on Vaccination Compliance on 185 Parents of Newborn Babies Conducted in Outpatient Clinics in Poland Between January 2022 and July 2022. (PubMed, Med Sci Monit) - "BACKGROUND This study aimed to evaluate, in outpatient clinics in Poland between January 2022 and July 2022, the effectiveness of the But-You-Are-Free (BYAF) social influence technique by healthcare professionals during interaction with 185 parents deciding about vaccinating (eg, Hexacima, Prevenor 13, Synflorix, Rotateq, Act Hib, Boostrix, Pentaxim, DTP, Imovax, Priorix, MMR, Tetracim, Adacel, Euvax B, Fuvax, FSME, Varilix, Nimenrix, Bexero vaccines) their babies. CONCLUSIONS The findings showed that participants who were exposed to the BYAF technique declared lower intentions to vaccinate their babies, and vaccinated them less often than those in the control condition. This result critically highlights that this technique should not be employed in the medical settings of pediatric vaccination."

Compliance • Journal • Pediatrics

Clearance of hepatitis C virus infection did not ameliorate the response to hepatitis B vaccine (EASL-ILC 2022) - "All the studied groups had received 3 intradeltoid, 20 μg, doses of HBV-vaccine (Euvax B, LG Life Sciences, Korea) given at 0,1 & 6 months... Patients with CHC demonstrate a significantly weak response to HBV-vaccine, particularly those with older age, fibrosis advancement and schistosomiasis. Treatment and SVR achievement did not ameliorate this response."

Fibrosis • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Arresting vertical transmission of hepatitis B virus (AVERT-HBV) in pregnant women and their neonates in the Democratic Republic of the Congo: a feasibility study. (PubMed, Lancet Glob Health) - P4 | "Adding HBV screening and treatment of pregnant women and infant birth-dose vaccination to existing HIV prevention of mother-to-child transmission platforms is feasible in countries such as the Democratic Republic of the Congo. Birth-dose vaccination against HBV infection integrated within the current Expanded Programme on Immunisation and HIV prevention of mother-to-child transmission programme could accelerate progress toward HBV elimination in Africa."

Clinical • Journal • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Pediatrics